Upright proton therapy completed without interruption in ten pediatric patients

All ten children completed upright proton therapy, including craniospinal irradiation, with no in-field progression at three months but limited long-term follow-up.

KEY POINTS

  • This single-institution observational study from Hadassah Medical Center, Jerusalem, evaluated 10 pediatric patients aged 2–18 years treated with upright image-guided proton therapy between January 2024 and December 2025. Diagnoses included three craniopharyngiomas, two medulloblastomas, two neuroblastomas, one chordoma, one rhabdomyosarcoma, and one retinoblastoma. Four patients received craniospinal irradiation (CSI), two had undergone previous radiotherapy, and five received concurrent chemotherapy.
  • Treatment was delivered using a gantry-less proton system with a fixed horizontal pencil beam scanning beamline, combined with a six-degree-of-freedom robotic positioning chair and vertical CT imaging. Treatment plans used Monte Carlo dose calculation and robust optimization. For CSI, two isocenters and three fields were connected through an 8-cm gradient-junction overlap, designed to reduce sensitivity to longitudinal positioning errors.
  • Daily volumetric image guidance and intratreatment verification were incorporated into the upright workflow. The analysis included 246 three-dimensional imaging sessions and 750 two-dimensional verification sessions. During 2D/3D verification, mean translational corrections were −0.4 ± 4.6 mm, −2.3 ± 3.0 mm, and +0.5 ± 4.0 mm across the three axes, with corresponding mean rotational corrections of −0.4°, −0.1°, and 0.0°. These values describe registration corrections rather than independently measured residual treatment-delivery errors.
  • All ten patients completed the prescribed treatment without interruption, including young children requiring monitored anesthesia care. No anesthesia-related complications were reported, and spontaneous breathing with continuous airway access was maintained. Total treatment-room time was approximately 60–90 minutes for anesthesia-assisted CSI, compared with 20–30 minutes for other pediatric treatments. Beam delivery required less than two minutes per field in most cases, increasing to approximately seven minutes for CSI.
  • The study reported generally acceptable target coverage, although individual DVH results require clarification. Focal prescriptions ranged from 45 to 70 Gy(RBE), while CSI schedules included 18–36 Gy(RBE) with focal boosts. In Table 3, the patient receiving 70 Gy(RBE) for clival chordoma had a reported CTV D95 of 53.90 Gy(RBE) and brainstem Dmax of 70.23 Gy(RBE). These values are not readily reconciled with the manuscript's general statement that CTV D95 closely matched prescription and should be clarified before drawing conclusions about uniform dosimetric compliance.
  • Early disease assessment showed no in-field progression at three months. Five patients demonstrated complete metabolic response, one partial metabolic response, and four stable disease. Acute toxicity was predominantly grade 1, including fatigue in 6/10 patients (60%), alopecia in 4/10 (40%), and headache in 2/10 (20%). One grade ≥3 hydrocephalus event (10%) was recorded, with no other grade ≥3 events reported. Most low-grade symptoms had resolved or improved by the first follow-up.
  • The findings establish early technical feasibility rather than comparative effectiveness. The cohort comprised only ten patients with heterogeneous diseases, prescriptions, and treatment volumes, and follow-up was limited to approximately three months for the reported clinical outcomes. No comparison with conventional gantry-based proton therapy assessed positioning accuracy, delivered dose, cost, tumor control, or late toxicity. The study also received support from the system manufacturer, and several authors disclosed related financial relationships.

CLINICAL TAKEAWAY

Gantry-less upright image-guided proton therapy appears feasible for selected pediatric patients, including those requiring craniospinal irradiation or monitored anesthesia care, with reproducible image-guided positioning and successful treatment completion. However, the small heterogeneous cohort, very short follow-up, and unresolved patient-level dosimetric discrepancy mean that this experience should be considered an early proof of concept rather than evidence of equivalence to conventional proton delivery.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction